Arrythmias Flashcards
Sinus bradycardia
ONLY TREAT IF SYMPTOMATIC
HR < 60
Impulses in the SA node
Decrease automaticity in the SA node
Hypotension, dizziness, fainting
Atropine 0.5-1 mg every 5 minutes, max of 3 mg if symptomatic
SE of atropine: tachycardia, constipation, dry mouth, blurred vision, urinary retention
OR: dopamine, epinephrine, isoproterenol
PACEMAKER if unwilling for pacemaker then theophylline
Atrial fibrillation
chest pains, palpitations, dizziness, light headedness, SOB, hypotension, angina, fatigue, HF exacerbation
Goal #1 is to prevent thrombosis leading to a stroke: anticoagulants
Goal #2 is to control ventricular rate: Non-DHP CCB, BB, Digoxin, Amiodarone
Goal #3 convert to NSR: ibutilite, amiodarone, procainamide, flecainide, propafenone, DCC
Goal #4 is to maintain NSR and to prevent recurrent episodes: dronedarone, dofetilide, flecainide, propafenone , amiodarone, sotalol
Ventricular rate: 120-180 bpm
Supraventricular tachycardia (SVT)
Types: paroxysmal SVT
Features: regular rhythm
HR: 110-250 bpm
Narrow QRS complexes
Single re-entry circuit in the AV node moving in a circular motion depolarizing ventricles but travelling back up to repolarize atria
Can also occur in the AV pathway, atria, and SA node
Neck pounding, palpitations, dizziness, lightheadedness, polyuria, syncope
Goal #1 Terminate SVT
Adenosine: 6-12-12
Diltiazem
Verapamil
BB
Premature ventricular complexes (PVC)
Widened QRS complex
NSR with occasional abnormal beats
Types:
Simple: isolated single PVC
Frequent: at least 1 PVC on a 12-lead ECG or > 30 PVCs/hour
Risk factors: ischemic heart disease, MI, anemia, hypoxia, cardiac surgery
Usually asymptomatic, palpitations, dizziness, lightheadedness
Treatment:
asymptomatic PVC should not be treated
BB, verapamil, diltiazem, cardiac ablation
Ventricular tachycardia
MONOMORPHIC TACHYCARDIA
Regular Rhythm
Wide QRS complex
HR: 100-250
Series of > 3 consecutive PVC’s at a rate > 100 bpm
Types: non-sustained, sustained, sustained + no structural heart disease
Mechanism: increase automaticity, re-entry within the ventricles
Risk factors: MI, CAD, HFrEF, electrolyte imbalance, drugs such as flecainide, propafenone, digoxin
Symptoms: asymptomatic (nonsustained VT), palpitations, dizziness, lightheadedness, angina, syncope, hypotension
Goal 1: Terminate VT, restore NSR
DCC is preferred, then procainamide, then IV Amiodarone or sotalol
verapamil and BB is for no structural heart disease
Goal 2: prevent recurrence and sudden cardiac death
- Implantable cardiac defibrillator (ICD)
outflow tract VT: BB
Ventricular fibrillation
Irregular, disorganized, chaotic electrical activity
No recognizable QRS complexes
Risk factors: MI, HFrEF, CAD
Symptoms: syndrome of sudden cardiac death
Goal: Terminate VF, restore NSR
The only effective treatment is defibrillation
Drugs are used to facilitate defibrillation
Drugs alone with not terminate VF
Defibrillation, Epinephrine, Amiodarone, Lidocaine
Defibrillation, CPR, DRUG–> repeat
How to read an ECG
P wave: atrial depolarization
QRS complex: ventricular depolarization, atrial repolarization is buried
T wave: ventricular reploarization
PR interval: conduction time of AV node
QT interval: repolarization
How to determine NSR
Is there a p wave in front of every QRS complex?
Is there a QRS complex after every p wave?
Is the interval between the R waves equal?
Is there HR between 60-100 bpm?
Normal ECG values
PR interval: 0.12-0.20 seconds (120-200 ms)
QRS duration: 0.08-0.12 seconds (80-120 ms)
QT interval: 0.38-0.46 seconds (380-460 ms)
QTc interval: 0.36-0.45 seconds (360-450 ms) – Men
QTc interval: 0.36-0.46 seconds (360-460 ms) - Women
Torsades de pointes
POLYMORPHIC TACHYCARDIA
When QTc > 0.5 seconds–> increased risk of drug-induced arrhythmia
What does QTc interval mean?
Corrected QT interval for HR
Slower HR: Longer QTc
Fater HR: slower QTc
Medications that can cause TdP
Antiarrhythmics
Macrolides, fluoroquinolones
Antidepressants, antipsychotics
Amiodarone
MOA: all 4 antiarrhythmic mechanisms
Both BB and CCB activity
AE: Hypotension, bradycardia, pulmonary fibrosis, blue/grey skin discoloration, corneal deposits, hepatotoxicity, hypothyroidism, photosensitivity
Drug interactions:
Inhibits Pgp: digoxin
Inhibits CYP: warfarin, statins
Monitoring: Dermatologic, corneal deposits, pulmonary fibrosis, QTC prolongation, hepatotoxicity, hypo,hyperthyroidism
Goal HR < 100-110 bpm and asymptomatic
Hemodynamically unstable criteria
SBP < 90
HR > or equal to 150 bpm
Loss of consciousness
Chest pain
ALWAYS USE DCC
Ibutilide
Class 3 antiarrhythmic blocking Ikr channel
AE: TdP
DO NOT USE IN HF
NEGATIVE INOTROPE